As a result, PD-L1 IHC is used as an eligibility biomarker in certain cancers (e.g., NSCLC, HNSCC, urothelial carcinoma) but not as an absolute exclusion criterion in others (e.g., melanoma). This evidence concerns the gene CD274 and non-small cell lung carcinoma.